GET DAILY SIGNALSTheriva Biologics (TOVX): Examining the Path to a $2.50 Analyst Target
Key Takeaways
- The $2.50 target represents the average of two current analyst estimates: $1.00 from Maxim Group and $4.00 from Alliance Global.
- At roughly $0.16 per share, reaching $2.50 would require an increase of more than 1,400%.
- The wide range between the two targets highlights differing views on the company’s clinical progress and financing needs.
- Positive elements include FDA alignment on a pivotal Phase 3 plan for VCN-01 and approval of the VIRAGE2 trial in pancreatic cancer.
- Key risks center on ongoing cash burn, share dilution from financings, and the high-stakes nature of clinical development.
- Additional context is available on the company’s Major News, Today’s Price Move, Forecast, and Earnings pages.
Understanding the Analyst Price Targets
The $2.50 figure comes directly from averaging the two published targets. Maxim Group’s Jason McCarthy issued a $1.00 target and upgraded the rating to Buy from Hold on March 31, 2026. Alliance Global maintained a Buy rating but reduced its target to $4.00 from $7.00 on March 13, 2026, after the fourth-quarter update. The resulting midpoint sits inside a broad $1-to-$4 range. Both firms remain positive overall, yet the spread reflects real differences in how each assesses the balance sheet and pipeline potential. I view this average as a simple midpoint rather than a formal consensus.
Where the Stock Stands Today
Shares have been trading near $0.16 in mid-November 2026, with the prior session closing around $0.1542. The 52-week range runs from approximately $0.14 to $0.49. A move to $2.50 would represent more than a 1,400% advance, an unusually large shift even for a small-cap name. Because revenue remains minimal and losses persist, any meaningful re-rating hinges primarily on clinical milestones and capital access rather than current earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Market capitalization currently sits between roughly $7 million and $11 million, and repeated equity offerings have increased the share count over time.
Factors That Could Help Reach the Target
- VCN-01 has produced a randomized Phase 2b survival signal in metastatic pancreatic cancer along with supporting peer-reviewed data.
- Regulatory alignment with the FDA on a pivotal Phase 3 design and approval of the VIRAGE2 trial represent important de-risking steps.
- A licensing or collaboration deal could bring non-dilutive capital and validate the commercial potential of the pipeline.
- Strong clinical readouts in areas of high unmet need could support a sharp re-rating given the current low valuation.
Risks That Could Hold It Back
- Continued operating losses and negative cash flow have led to repeated financings that dilute existing shareholders.
- Clinical-stage programs carry binary outcomes; an unsuccessful or inconclusive trial could significantly reduce value.
- Governance and financing uncertainties, including quorum issues tied to warrant proposals, add timing risk around capital raises.
- The stock has declined more than 40% over the past year and trades below both the 50-day and 200-day moving averages, leaving sentiment weak.
Technical Picture and Key Levels
The 52-week range of roughly $0.14 to $0.49 frames the current technical structure. The $0.14 area serves as near-term support, while $0.49 remains the major resistance level. Intermediate psychological markers such as $0.25, $0.50, and $1.00 would likely need to be cleared on any sustained advance. With the price below longer-term moving averages, the prevailing trend stays downward. From what I see, any path toward $2.50 would first require reclaiming these levels.
Key Things to Watch Going Forward
Analyst targets generally reflect a 12-month horizon. The most relevant catalysts include quarterly results and guidance, updates on VIRAGE2 enrollment and VCN-01 data, financing announcements, analyst revisions, and any partnership or regulatory news. For a clinical-stage company, trial outcomes and capital activity will likely matter more than near-term revenue or EPS figures. I’m watching this closely as those events unfold.
AI Daily Buy/Sell Signals
In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get an additional perspective on momentum shifts for names like this. The tool applies AI to scan market conditions and technical patterns across thousands of securities. It can be a useful complement to fundamental analysis for volatile biotech stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TOVX turns negative, indicating new downward trend
TOVX saw its Momentum Indicator move below the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 87 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TOVX turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 48 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TOVX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TOVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TOVX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for TOVX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 65 of 75 cases where TOVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
TOVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.627) is normal, around the industry mean (3.498). P/E Ratio (0.116) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (23.753) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. TOVX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TOVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement